


**Product Name** : AZD 4205  
**Cat. No.** : PC-61986  
**CAS No.** : 2091134-68-6  
**Molecular Formula** : C<sub>25</sub>H<sub>31</sub>N<sub>9</sub>O<sub>2</sub>  
**Molecular Weight** : 521.601  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



2. Patent: WO 2017050938 A1 20170330, Example 32.

## Biological Activity

Golidocitinib (AZD4205) is a potent, selective **JAK1** inhibitor IC<sub>50</sub> of 73 nM and K<sub>i</sub> of 2.8 nM, shows high selectivity against JAK2 and JAK3 with IC<sub>50</sub> of 13,233 nM and >30,000 nM respectively.

Golidocitinib (AZD4205) shows potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC<sub>50</sub> of 128 nM and excellent selectivity across the kinome.

Golidocitinib (AZD4205) reduces residual disease and prolongs the benefit of Osimertinib in lung cancer patients with EGFR activating mutations both in vitro and in vivo.

## References

Jason G. Kettle, et al. **AACR** Abstract 979: Discovery of the JAK1 selective kinase inhibitor AZD4205.

